Skip to main content

COVID-19

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article
Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://t.co/yVWGRr6jfr

Dr. John Cush RheumNow ( View Tweet)

Oct 23, 2020

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Oct 23, 2020

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article

Remdesivir FDA Approved for Hospitalized COVID-19

Oct 22, 2020

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.



FDA approved its 1st drug to treat COVID-19 -

Read Article
FDA approved its 1st drug to treat COVID-19 - the antiviral drug Veklury (remdesivir) for for acute care treatment of COVID-19 requiring hospitalization. Approval based on 3 clinical trials showing clinical improvement, but no change in mortality rates.

Dr. John Cush RheumNow ( View Tweet)

Oct 22, 2020
Study from NY shows that Death rates from COVID-19 have dropped (in hospitalized pts) from a high of 27% down to 3%. Partly because a younger, healthier are now getting infected, arriving @ hospital w/ less-severe Sxs.

Dr. John Cush RheumNow ( View Tweet)

Oct 22, 2020
#LTF Listen to Fauci

Dr. John Cush RheumNow ( View Tweet)

Oct 22, 2020

Clinical Trial Boom or Bust in Severe COVID-19

Oct 20, 2020

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.



Remdesivir

Read Article

Outpatient Visits Return to Pre-COVID Rates

Oct 19, 2020

The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.

Read Article
Pre Print of UK research suggests biomarkers for Severe COVID-19 includes markers of myeloid or endothelial activation; such as D-dimer, EN-RAGE, CXCL10, GM-CSF, IL-6, TNF-α, IL-2, GDF-15, G-CSF, S100A12, https://t.co/Yv6yM4DYmp

Dr. John Cush RheumNow ( View Tweet)

Oct 16, 2020

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Oct 15, 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
There have been many cases of Kawasaki vasculitis in kids ith COVID-19; now Lg vessel vasculitis in 79 yo Japanese man w/ COVID-19 pneumonia, CRP 17.7 mg/dL, spiking fevers and CTA and FDG-PET evid of aortic and LVV, neg ANCA, nl IgG4, but was HLA-DR4+.

Dr. John Cush RheumNow ( View Tweet)

Oct 14, 2020

COVID Transmission from Young to Old

Oct 13, 2020

The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots. Among 767 hotspot counties identified during June and July 2020, early increases in the percent positivity among persons aged ≤24 years were

Read Article
Observational study of 123 Spanish rheumatic dz pts w/ COVID-19, finds 54 hospitalized. Admitted pts were 69.7 yrs, and 22% died. Admission was assoc w/ older age, autoimmune dz (vs inflammatory arthritis; OR: 3.55), but not DMARD Rx. https://t.co/UWNyhOKbvF

Dr. John Cush RheumNow ( View Tweet)

Oct 13, 2020
The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus?

Dr. John Cush RheumNow ( View Tweet)

Oct 11, 2020

Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients

Oct 09, 2020

The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.



A total of 4716 patients who were hospitalized with Covid-19 were randomly to

Read Article
Another case of COVID-19 Arthritis; 58 yoF w/ non-severe COVID-19, (by qRT-PCR ) had arthralgia, fever, cough, nausea, diarrhoea, dysgeusia, and devloped ankle arthritis CRP 7·36 mg/L, lymphopenia (1·29) persistent arthritis (by US) and +Sars-CoV-2 in SF.

Dr. John Cush RheumNow ( View Tweet)

Oct 09, 2020

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

Oct 08, 2020

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Comparison of 34,128 COVID and 84,585 influenza pts; COVID-19 patients have been more typically been male, younger, and have fewer comorbidities and lower medication use than flu. (data from USA, South Korea, Spain) https://t.co/VUzVxFdBra

Dr. John Cush RheumNow ( View Tweet)

Oct 08, 2020
To quash the virus, the immune system unleashes an arsenal. Sometimes these weapons turn inward and destroy healthy tissues. Combatting this friendly fire has become as crucial a part of the Covid-19 treatment strategy as subduing the virus itself.

NYT Health NYTHealth ( View Tweet)

Oct 06, 2020

Systemic Steroids Reduce Mortality in COVID-19

Oct 06, 2020

JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.

Read Article
https://t.co/0bh6Mh2pKP
Adam Cifu adamcifu ( View Tweet)
Oct 05, 2020

RheumNow Podcast – Function Follows Form (10.2.20)

Oct 01, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.

Read Article
Latest data Global Rheumatology Alliance COVID Registry -2121 pts (40% RA, 17% SLE, 9% PsA), 64% on DMARDs, 33% biologics, 5% JAKi, 34% steroid,27% HCQ, with only 7.6 deaths and 39% hospitalized and 81% resolved infection. https://t.co/g0w4QZHmRl

Dr. John Cush RheumNow ( View Tweet)

Oct 01, 2020
×